Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $41.6 million.

  • Atara Biotherapeutics' Other Non-Current Liabilities rose 94928.19% to $41.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year increase of 94928.19%. This contributed to the annual value of $39.0 million for FY2024, which is 1120.42% up from last year.
  • Atara Biotherapeutics' Other Non-Current Liabilities amounted to $41.6 million in Q3 2025, which was up 94928.19% from $40.8 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Other Non-Current Liabilities registered a high of $41.6 million during Q3 2025, and its lowest value of $616000.0 during Q1 2022.
  • Over the past 4 years, Atara Biotherapeutics' median Other Non-Current Liabilities value was $5.5 million (recorded in 2022), while the average stood at $16.1 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 1813.12% in 2024, then soared by 94928.19% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' Other Non-Current Liabilities (Quarter) stood at $5.6 million in 2022, then soared by 530.41% to $35.1 million in 2023, then grew by 11.2% to $39.0 million in 2024, then grew by 6.77% to $41.6 million in 2025.
  • Its Other Non-Current Liabilities was $41.6 million in Q3 2025, compared to $40.8 million in Q2 2025 and $39.9 million in Q1 2025.